NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis → The ONE AI Sock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free DSGN Stock Alerts $4.03 +0.12 (+3.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.84▼$4.0950-Day Range$2.27▼$4.0352-Week Range$1.94▼$8.47Volume220,935 shsAverage Volume311,789 shsMarket Capitalization$227.65 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Design Therapeutics alerts: Email Address Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside36.5% Upside$5.50 Price TargetShort InterestHealthy6.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 20 Articles This WeekInsider TradingAcquiring Shares$99,750 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.25) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector377th out of 938 stocksPharmaceutical Preparations Industry180th out of 441 stocks 3.0 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Design Therapeutics has a forecasted upside of 36.5% from its current price of $4.03.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.52% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Design Therapeutics has recently decreased by 24.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 3.9 News and Social Media Coverage News SentimentDesign Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Design Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for DSGN on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.80% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.25) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Sock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesMarch 26, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid Purchases 9,156 SharesMarch 26, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in StockMarch 29, 2024 | Weiss Ratings (Ad)The ONE AI Sock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …March 27, 2024 | finance.yahoo.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 26, 2024 | msn.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 23, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Design Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:DSGN)March 23, 2024 | americanbankingnews.comLeerink Partnrs Analysts Lift Earnings Estimates for Design Therapeutics, Inc. (NASDAQ:DSGN)March 23, 2024 | americanbankingnews.comBrokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) PT at $5.50March 29, 2024 | Weiss Ratings (Ad)The ONE AI Sock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …March 22, 2024 | americanbankingnews.comDesign Therapeutics, Inc. to Post FY2025 Earnings of ($1.22) Per Share, Leerink Partnrs Forecasts (NASDAQ:DSGN)March 21, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)March 21, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program UpdatesMarch 21, 2024 | americanbankingnews.comWedbush Reaffirms Neutral Rating for Design Therapeutics (NASDAQ:DSGN)March 21, 2024 | americanbankingnews.comRoyal Bank of Canada Reaffirms "Sector Perform" Rating for Design Therapeutics (NASDAQ:DSGN)March 20, 2024 | stockhouse.comDesign Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | investorplace.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline ProgressMarch 19, 2024 | globenewswire.comDesign Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | investing.comDesign Therapeutics Inc (DSGN)March 18, 2024 | benzinga.comEarnings Preview For Design TherapeuticsMarch 15, 2024 | finance.yahoo.comDSGN Jul 2024 2.500 putMarch 15, 2024 | finance.yahoo.comDSGN Apr 2024 7.500 putMarch 12, 2024 | globenewswire.comDesign Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateFebruary 9, 2024 | benzinga.comSR ONE CAPITAL PARTNERS I, LP's Net WorthDecember 18, 2023 | finance.yahoo.comDesign Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowDecember 7, 2023 | morningstar.comDesign Therapeutics Inc DSGNNovember 25, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Design Therapeutics StockSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+36.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.82% Return on Assets-21.82% Debt Debt-to-Equity RatioN/A Current Ratio29.58 Quick Ratio29.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.96 per share Price / Book0.81Miscellaneous Outstanding Shares56,494,000Free Float40,789,000Market Cap$227.67 million OptionableOptionable Beta1.72 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 54)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $638.46kDr. Sean Jeffries Ph.D. (Age 44)Chief Operating Officer Comp: $572.21kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorKey CompetitorsIncannex HealthcareNASDAQ:IXHLAbeona TherapeuticsNASDAQ:ABEOAlimera SciencesNASDAQ:ALIMCapricor TherapeuticsNASDAQ:CAPRInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsJohn P SchmidBought 17,809 shares on 3/25/2024Total: $66,605.66 ($3.74/share)John P SchmidBought 9,156 shares on 3/22/2024Total: $33,144.72 ($3.62/share)Vanguard Group Inc.Bought 10,448 shares on 3/11/2024Ownership: 1.781%Goldman Sachs Group Inc.Bought 579,225 shares on 3/1/2024Ownership: 1.828%GSA Capital Partners LLPBought 28,711 shares on 2/16/2024Ownership: 0.129%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions Should I buy or sell Design Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. What is Design Therapeutics' stock price target for 2024? 7 brokers have issued 1-year price objectives for Design Therapeutics' shares. Their DSGN share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 36.5% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. How have DSGN shares performed in 2024? Design Therapeutics' stock was trading at $2.65 on January 1st, 2024. Since then, DSGN stock has increased by 52.1% and is now trading at $4.03. View the best growth stocks for 2024 here. Are investors shorting Design Therapeutics? Design Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 2,140,000 shares, a decline of 24.9% from the February 29th total of 2,850,000 shares. Based on an average daily volume of 259,700 shares, the short-interest ratio is currently 8.2 days. Currently, 6.5% of the company's shares are short sold. View Design Therapeutics' Short Interest. When is Design Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our DSGN earnings forecast. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.07. What ETFs hold Design Therapeutics' stock? ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Neuroscience and Healthcare ETF (IBRN). When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Design Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BML Capital Management LLC (1.84%), Goldman Sachs Group Inc. (1.83%), Goldman Sachs Group Inc. (1.83%), Vanguard Group Inc. (1.78%), Vanguard Group Inc. (1.78%) and Northern Trust Corp (0.67%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, John P Schmid, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.